Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.64 | N/A | -6.51% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.64 | N/A | -6.51% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding future performance without providing specific guidance. They emphasized their commitment to advancing clinical programs.
Management did not provide specific guidance for the upcoming quarters.
The company is focusing on its ongoing clinical trials and product development.
Nektar Therapeutics reported a larger-than-expected loss per share, which contributed to a 4.09% decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's short-term outlook. The management's focus on clinical trials suggests they are prioritizing long-term growth over immediate financial performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ONEOK INC NEW
Feb 24, 2020